Group One Trading
FATE icon

Group One Trading’s Fate Therapeutics FATE Stock Holding History

Group One Trading’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2K Buy
9,305
+4,874
+110% +$5.93K ﹤0.01% 6317
2025
Q4 		$4.35K Buy
4,431
+1,600
+57% +$1.92K ﹤0.01% 7241
2025
Q3 		$3.57K Buy
+2,831
New +$3.05K ﹤0.01% 7698
2025
Q1 		– Sell
-8,728
Closed -$10.7K – 7815
2024
Q4 		$14.4K Buy
8,728
+6,611
+312% +$16.7K ﹤0.01% 5906
2024
Q3 		$7.41K Buy
+2,117
New +$8.24K ﹤0.01% 5731
2024
Q2 		– Sell
-1,050
Closed -$4.6K – 6944
2024
Q1 		$7.71K Sell
1,050
-15,639
-94% -$96.8K ﹤0.01% 6001
2023
Q4 		$62.4K Buy
16,689
+10,400
+165% +$24.5K ﹤0.01% 4891
2023
Q3 		$13.3K Buy
+6,289
New +$20.8K ﹤0.01% 6168
2023
Q1 		– Sell
-2,654
Closed -$16K – 7409
2022
Q4 		$26.8K Buy
2,654
+419
+19% +$7.87K ﹤0.01% 5428
2022
Q3 		$50K Sell
2,235
-9,201
-80% -$266K ﹤0.01% 5402
2022
Q2 		$283K Buy
11,436
+5,200
+83% +$143K ﹤0.01% 3960
2022
Q1 		$242K Buy
+6,236
New +$241K ﹤0.01% 4598
2021
Q3 		– Sell
-5,427
Closed -$426K – 8336
2021
Q2 		$471K Buy
+5,427
New +$437K ﹤0.01% 4281
2020
Q4 		– Sell
-1,691
Closed -$105K – 6637
2020
Q3 		$68K Sell
1,691
-5,373
-76% -$188K ﹤0.01% 4442
2020
Q2 		$242K Sell
7,064
-19,258
-73% -$574K ﹤0.01% 3227
2020
Q1 		$585K Buy
26,322
+23,730
+916% +$600K ﹤0.01% 1942
2019
Q4 		$51K Buy
2,592
+2,328
+882% +$37K ﹤0.01% 3994
2019
Q3 		$4K Sell
264
-1,200
-82% -$23K ﹤0.01% 4805
2019
Q2 		$30K Sell
1,464
-2,900
-66% -$52.3K ﹤0.01% 4020
2019
Q1 		$77K Sell
4,364
-3,361
-44% -$53.1K ﹤0.01% 3338
2018
Q4 		$99K Buy
+7,725
New +$108K ﹤0.01% 3157
2018
Q3 		– Sell
-23,312
Closed -$276K – 5307
2018
Q2 		$264K Buy
+23,312
New +$257K ﹤0.01% 2825

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's FATE Position: Q1 2026 in Review

Group One Trading increased its Fate Therapeutics (FATE) stake by 110% in Q1 2026, buying an estimated $5.93K and bringing the position to 9,305 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6317.

Group One Trading first reported a position in FATE in Q2 2018 and has held it in 22 quarters since. The position peaked at $585K in Q1 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Group One Trading held 9,305 shares of Fate Therapeutics worth $11.2K as of Q1 2026.
  • Group One Trading bought 4,874 Fate Therapeutics shares in Q1 2026, an estimated $5.93K.
  • Fate Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6317 holding.
  • Group One Trading first reported a position in Fate Therapeutics in Q2 2018 and has held it in 22 quarters since.
  • Group One Trading's Fate Therapeutics position peaked at $585K in Q1 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.